Silence Therapeutics PLC (NAS:SLN)
$ 22.4 0.07 (0.31%) Market Cap: 1.05 Bil Enterprise Value: 973.87 Mil PE Ratio: 0 PB Ratio: 41.48 GF Score: 49/100

Full Year 2019 Silence Therapeutics PLC Earnings Call Transcript

Apr 14, 2020 / 12:00PM GMT
Operator

(technical difficulty)

Iain Gladstone Ross
Silence Therapeutics plc - Executive Chairman

Hi. Good afternoon, everybody. I'm very pleased to be able to present the 2019 results for Silence Therapeutics. I think this is quite an extraordinary time, so I hope that everybody on the call is safe and well. We have been continuing to go forward with the business, and perhaps we can cover that a little bit further.

But going to the first slide, obligation is to show you the safe harbor statement and to say that everything in this call is governed by that statement.

If I move to the agenda, what I would like to do is make a few opening remarks, and then I'm going to ask Rob Quinn, our Chief Financial Officer, to take you through the results. And then as Heidi has said, we'll have a Q&A session. So I'm Iain Ross, I'm the Interim Executive Chairman, and I'll cover how we're getting on with the CEO recruitment in a few minutes. We also have Dr. Giles Campion, who's our Head of R&D and Chief Medical Officer; and also Dr. John Strafford, who is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot